Enanta Pharmaceuticals | ENTA - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Amgen USD 5.87B 1.02B 2026-03
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 75.25M 1.52M 2026-06
AstraZeneca USD 12.86B 251M 2026-06
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
Biogen USD 2.12B 307M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Immunic 0 0 2025-03
Incyte USD 1.57B 400.89M 2026-06
Insmed USD 356.19M 99.73M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
J&J USD 18.55B 1.31B 2026-06
Karyopharm Therapeutics USD 33.72M 1.13M 2026-03
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
Merck USD 12.09B 1.24B 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD -248M 11.29B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Roche Holding CHF 22.69B 600M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06